tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate, 95.0%, 500mg

3-((TERT-BUTOXYCARBONYL)AMINO)PIPERIDINE-3-CARBOXYLIC ACID, 95.0%, 5g

3-(4-Bromopyrazol-1-yl)benzoic acid, 97%, 1g

2-Methoxybenzenethiol, 97.0%, 100g

3-Nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 97.0%, 5g

6-nitro-N-(pyridin-2-ylmethyl)-1,3-benzothiazol-2-amine, 95.0%, 250mg

(S)-3-(TERT-BUTYL)-4-(2-METHOXYPHENYL)-2,3-DIHYDROBENZO[D][1,3]OXAPHOSPHOLE, 95%, 100mg

2-Bromo-6-(dimethylamino)benzaldehyde, 98%, 1g

2-Chloro-3-fluoro-4-methylpyridine, 95.0%, 500g

Methyl (S)-1-Boc-pyrrolidine-3-carboxylate, 95.0%, 5g

iScope IS.1152-PLPHi Biocular with Plan phase IOS objectives and Rackless cross table (infinity)

4-Nitro-1H-pyrrolo[2,3-b]pyridine 7-oxide, 95.0%, 250mg

{2-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]ethyl}amine hydrochloride, 95.0%, 100mg